NAA20

N-alpha-acetyltransferase 20, NatB catalytic subunit P61599 NAA20_HUMAN
Protein Coding Chr 20 20p11.23 Swiss-Prot reviewed Entrez 51126
Mutations
132
CL 14 · Tissue 117
Samples
57
CL 10 · Tissue 46
Peptides
49
unique mutant peptides
Transcripts
3
isoforms mutated

Stats by Source

Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)

How the counts split by source
Stats by Source

Total = all mutations for this gene across every source.

Cell line = COSMIC Cell Lines Project + DepMap + PubMed.

Tissue = COSMIC primary-tissue (patient tumour) samples.

Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.

TotalCell lineTissue
Mutations13214117
Samples571046
Peptides49643

Function

NAA20 · N-alpha-acetyltransferase 20, NatB catalytic subunit

NAT5 is a component of N-acetyltransferase complex B (NatB). Human NatB performs cotranslational N(alpha)-terminal acetylation of methionine residues when they are followed by asparagine (Starheim et al., 2008 [PubMed 18570629]).[supplied by OMIM, Apr 2009].

Isoforms & Proteins

3 transcripts · UniProt mapping is sequence-verified (AA-safe)

About the isoform mapping
Isoforms & Proteins

Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.

The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.

Counts are mutations and unique mutant peptides on each transcript.

TranscriptUniProtMutationsPeptides
ENST00000334982 P61599 55 41
ENST00000398602 A8MZB2* 46 36
ENST00000310450 P61599-2 31 21

Gene Properties

Type
Protein Coding
Chromosome
20
Cytoband
20p11.23
Entrez ID
Aliases
MRT73NAT3NAT3PNAT5NAT5PdJ1002M8.1

Recurrent Mutations

All 41 amino-acid changes on canonical ENST00000334982 · needle height = samples · drag the mini-map to zoom

What this lollipop shows
Recurrent Mutations

A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).

X-axis = amino-acid position in the protein.

Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.

The most recurrent changes are labelled; hover any needle for the change, position and counts.

Mutation frequency across cancer types

% of samples with a missense/complex mutation in NAA20 · cell line vs tissue

How this frequency is counted
Cancer-type mutation frequency

For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in NAA20 – counted as distinct samples (a sample counts once no matter how many mutations it has).

Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.

Cancer typeCell linesTissue samples
Endometrial Carcinoma
0/42 0%
8/612 1%
Burkitts Lymphoma
1/32 3%
0/196 0%
Gastric Carcinoma
0/74 0%
8/1809 0%
Colorectal Carcinoma
5/143 4%
9/3239 0%
Plasma Cell Myeloma
0/44 0%
1/305 0%
Melanoma
2/210 1%
3/1899 0%
Cervical Carcinoma
0/35 0%
1/422 0%
Wilms Tumour
0/5 0%
1/474 0%
Glioma
0/52 0%
3/2127 0%
Squamous Cell Lung Carcinoma
0/57 0%
1/810 0%
Other Solid Cancers
1/94 1%
1/1515 0%
Head and Neck Carcinoma
0/85 0%
2/1574 0%
Ovarian Carcinoma
0/109 0%
1/998 0%
Prostate Carcinoma
0/13 0%
2/2105 0%
Non-Small Cell Lung Carcinoma
0/304 0%
1/1390 0%
Breast Carcinoma
0/144 0%
2/3264 0%
Kidney Carcinoma
0/85 0%
1/1862 0%
Hepatocellular Carcinoma
0/46 0%
1/2210 0%
B-Lymphoblastic Leukemia
1/55 2%
0/2640 0%
B-Cell Non-Hodgkins Lymphoma
0/88 0%
1/2534 0%

Mutation Distribution

Where NAA20 is mutated · all tissues, split by cell line vs tissue

Mutation counts by tissue
Mutation Distribution

How many mutations in NAA20 were found in each tissue, across the whole database.

Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.

This shows the cancer-context where this gene is recurrently altered.

GTEx Expression

Median TPM across 54 healthy tissues

GTEx Portal ↗
About the expression data
GTEx Expression

Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.

Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.

Scroll or drag the mini-axis below the chart to browse all tissues.

Mutations

All 132 mutations in NAA20

About the mutation list
Mutations

Every mutation record for this gene, across all samples and sources.

The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).

Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.

IDSampleTranscriptAA Change CDSTypeSourceMutant PeptideWild-type Peptide